Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Roivant will sell its po­ten­tial block­buster ul­cer­a­tive col­i­tis drug to Roche for $7.1 bil­lion, less than a year af­ter ac­quir­ing it from Pfiz­er for what was ef­fec­tive­ly pen­nies on the dol­lar and af­ter months of news re­ports hint­ing that a deal of that size was in the works.

The Swiss Big Phar­ma nabs a drug that could com­pete with Mer­ck’s $10.8 bil­lion pur­chase of Prometheus Bio­sciences ear­li­er this year and Sanofi’s $1.5 bil­lion pact with Te­va. Their drugs are all TL1A in­hibitors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER